Livzon Pharmaceutical Group continues A-share repurchases

Livzon Pharmaceutical Group announced significant A-share repurchases on the Shenzhen Stock Exchange, buying back 129,300 A-shares on September 25, 2025. These repurchases were executed at prices ranging from RMB 38.49 to RMB 38.76 per share, totaling an expenditure of RMB 4,997,591. The acquired shares are currently designated as "to be cancelled" and are held as treasury stock.

This latest transaction follows a consistent pattern of daily A-share repurchases throughout 2024 and 2025. For instance, the company repurchased 145,700 A-shares on December 25, 2024, at RMB 37.75, and 144,400 A-shares on December 31, 2024, at RMB 38.08. Earlier in 2025, notable repurchases included 561,400 A-shares on January 14 at RMB 35.62, and 558,400 A-shares on February 13 at RMB 35.81. The aggregate of shares to be cancelled underscores the company's commitment to its share repurchase program.

The company's issued H-shares remained unchanged at 299,807,117 as of September 25, 2025, with no corresponding repurchases on the Hong Kong Stock Exchange. All repurchases were conducted on the Shenzhen Stock Exchange.